$BDPT
BIOADAPTIVES, INC. Stock $bdpt

$bdpt Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000164033424000602 Filed on April 10, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$11.99K	$7.200K	$28.57K
YoY Change	255.27%	80.9%	66.34%
Cost Of Revenue	$8.393K	$4.500K	$17.75K
YoY Change	501.22%	52.54%	76.62%
Gross Profit	$3.601K	$2.700K	$10.82K
YoY Change	81.87%	162.14%	51.84%
Gross Profit Margin	30.02%	37.5%	37.87%
Selling, General & Admin	$51.49K	$75.30K	$211.6K
YoY Change	153.77%	172.33%	-42.33%
% of Gross Profit	1429.88%	2788.89%	1955.36%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.940K	-$10.82K	$28.17K
YoY Change	189.55%	-1668.12%	-54.67%
% of Gross Profit	53.87%	-400.74%	260.35%
Operating Expenses	$53.43K	$64.48K	$239.7K
YoY Change	154.99%	127.52%	-44.12%
Operating Profit	-$49.83K	-$61.78K	-$228.9K
YoY Change	162.62%	126.22%	-45.74%
Interest Expense	$54.62K	-$355.0K	-$470.3K
YoY Change	6.96%	36126.53%	-262.68%
% of Operating Profit
Other Income/Expense, Net	-$256.9K		-$483.5K
YoY Change	-4.23%		2.08%
Pretax Income	-$306.7K	-$268.3K	-$712.5K
YoY Change	6.8%	848.73%	-20.45%
Income Tax
% Of Pretax Income
Net Earnings	-$306.7K	-$268.3K	-$712.5K
YoY Change	6.8%	848.73%	-20.45%
Net Earnings / Revenue	-2557.17%	-3726.39%	-2493.77%
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	972.2M shares	776.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.60K	$60.78K	$60.78K
YoY Change	227.76%	138.82%	138.82%
Cash & Equivalents	$19.60K	$60.78K
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$2.500K	$12.50K	$12.50K
YoY Change
Inventory	$18.57K	$15.28K	$15.28K
Prepaid Expenses	$0.00	$10.00K
Receivables
Other Receivables
Total Short-Term Assets	$40.67K	$88.56K	$88.56K
YoY Change	279.39%	158.01%	158.04%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$18.00K	$15.17K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$18.00K	$15.44K	$15.44K
YoY Change	675.86%	416.39%	416.39%
TOTAL ASSETS
Total Short-Term Assets	$40.67K	$88.56K	$88.56K
Total Long-Term Assets	$18.00K	$15.44K	$15.44K
Total Assets	$58.67K	$104.0K	$104.0K
YoY Change	349.93%	178.72%	178.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.280K	$443.6K	$443.6K
YoY Change	99.51%	6292.56%	8.21%
Accrued Expenses	$146.0K	$138.0K
YoY Change	14223.16%	13491.63%
Deferred Revenue
YoY Change
Short-Term Debt	$320.8K	$329.2K	$329.2K
YoY Change	-10.3%	-16.03%	-16.03%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.857M	$1.751M	$1.751M
YoY Change	12.95%	17.59%	17.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.857M	$1.751M	$1.751M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.857M	$1.751M	$1.751M
YoY Change	12.95%	17.59%	17.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.571M	-$8.264M
YoY Change	9.34%	9.43%
Common Stock	$115.5K	$89.58K
YoY Change	199.99%	254.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.798M	-$1.647M	-$1.647M
YoY Change
Total Liabilities & Shareholders Equity	$58.67K	$104.0K	$104.0K
YoY Change	349.93%	178.72%	178.75%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$306.7K	-$268.3K	-$712.5K
YoY Change	6.8%	848.73%	-20.45%
Depreciation, Depletion And Amortization	$1.940K	-$10.82K	$28.17K
YoY Change	189.55%	-1668.12%	-54.67%
Cash From Operating Activities	-$41.18K	-$91.29K	-$223.8K
YoY Change	111.61%	231.96%	-1.54%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$178.1K
YoY Change			-34.42%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	259.1K
YoY Change		-100.0%	52.68%
NET CHANGE
Cash From Operating Activities	-$41.18K	-91.29K	-223.8K
Cash From Investing Activities
Cash From Financing Activities		0.000	259.1K
Net Change In Cash	-$41.18K	-91.29K	35.37K
YoY Change	111.61%	-1317.2%	-161.48%
FREE CASH FLOW
Cash From Operating Activities	-$41.18K	-$91.29K	-$223.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	15441	usd
CY2023Q4	us-gaap	Assets Assets	103998	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	443579	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1750629	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	25255	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7551679	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6527428	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8264145	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1646631	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-895570	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	10050	usd
CY2022	us-gaap	Gross Profit GrossProfit	7126	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	254119	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	112759	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25405	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	42	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	15281	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001575142
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	252554765	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	895760225	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10000	shares
CY2023	bdpt	Share Based Goods And Nonemployee Service Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServiceTransactionValuationMethodExpectedDividendRate	0	pure
CY2022	bdpt	Share Based Goods And Nonemployee Service Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServiceTransactionValuationMethodExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-54949
CY2023	dei	Entity Registrant Name EntityRegistrantName	BioAdaptives, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-2592228
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2620 Regatta Drive
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 102
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Las Vegas
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2023	dei	City Area Code CityAreaCode	702
CY2023	dei	Local Phone Number LocalPhoneNumber	659-8829
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	358300	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	972160641	shares
CY2023	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2023	dei	Auditor Firm AuditorFirmId	5041
CY2023	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60776	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	8877	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	2500	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	88557	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	34324	usd
CY2022Q4	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	2990	usd
CY2022Q4	us-gaap	Assets Assets	37314	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	409920	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	977872	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	686856	usd
CY2023Q4	bdpt	Discount On Convertible Notes DiscountOnConvertibleNotes	52592	usd
CY2022Q4	bdpt	Discount On Convertible Notes DiscountOnConvertibleNotes	7647	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	321658	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	381793	usd
CY2023Q4	bdpt	Notes Payable Related Parties Classified As Current NotesPayableRelatedPartiesClassifiedAsCurrent	7520	usd
CY2022Q4	bdpt	Notes Payable Related Parties Classified As Current NotesPayableRelatedPartiesClassifiedAsCurrent	10246	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1750629	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1488815	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1488815	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	895760225	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	252554765	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	89576	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6074763	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1451501	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103998	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37314	usd
CY2023	us-gaap	Revenues Revenues	28565	usd
CY2022	us-gaap	Revenues Revenues	17176	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	17746	usd
CY2023	us-gaap	Gross Profit GrossProfit	10819	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	101478	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	110088	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	28174	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	62148	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	239740	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	429026	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-228921	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-421900	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-42	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-148	usd
CY2023	us-gaap	Interest Expense InterestExpense	162891	usd
CY2022	us-gaap	Interest Expense InterestExpense	289121	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-307412	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-184401	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13200	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-483545	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-473670	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-712466	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-895570	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-712466	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-895570	usd
CY2023	bdpt	Basic And Diluted Earning Per Share BasicAndDilutedEarningPerShare	-0.00
CY2022	bdpt	Basic And Diluted Earning Per Share BasicAndDilutedEarningPerShare	-0.01
CY2023	bdpt	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	559069032	shares
CY2022	bdpt	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	106011449	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1093039	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	521679	usd
CY2022	bdpt	Debts Forgiveness Related Party DebtsForgivenessRelatedParty	10000	usd
CY2022	bdpt	Warrant Issued For Patent S Acquisition WarrantIssuedForPatentSAcquisition	5429	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1451501	usd
CY2023	bdpt	Series A Preferred Stock Issued For License Fee Amount SeriesAPreferredStockIssuedForLicenseFeeAmount	22625	usd
CY2023	bdpt	Series B Preferred Stock Issued For License Fee Amount SeriesBPreferredStockIssuedForLicenseFeeAmount	18000	usd
CY2023	bdpt	Series B Preferred Stock Issued For Settlement Of Debt Related Party Amount SeriesBPreferredStockIssuedForSettlementOfDebtRelatedPartyAmount	16500	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	178100	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	282111	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-712466	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1646631	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-712466	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-895570	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-307412	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-184401	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	28174	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	62148	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	119555	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	239186	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13200	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-42	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-148	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6404	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4127	usd
CY2023	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-2500	usd
CY2022	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	10000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	39684	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	183752	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-470	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	1803	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-223773	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-227259	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	178100	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	51044	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1623	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	50000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1623	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	25272	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	80000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	195000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	259144	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	169728	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	35371	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-57531	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25405	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82936	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60776	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25405	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	4728	usd
CY2023	bdpt	Derivative Liability Recognized As Debt Discount DerivativeLiabilityRecognizedAsDebtDiscount	150000	usd
CY2022	bdpt	Derivative Liability Recognized As Debt Discount DerivativeLiabilityRecognizedAsDebtDiscount	217000	usd
CY2023	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	282111	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	521679	usd
CY2023	bdpt	Series A Preferred Stock Issued For License Fee SeriesAPreferredStockIssuedForLicenseFee	22625	usd
CY2022	bdpt	Series A Preferred Stock Issued For License Fee SeriesAPreferredStockIssuedForLicenseFee	0	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	18000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	16500	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2023	bdpt	Forgiveness Of Debt Related Party ForgivenessOfDebtRelatedParty	0	usd
CY2022	bdpt	Forgiveness Of Debt Related Party ForgivenessOfDebtRelatedParty	10000	usd
CY2023	us-gaap	Standard Product Warranty Accrual Additions From Business Acquisition StandardProductWarrantyAccrualAdditionsFromBusinessAcquisition	0	usd
CY2022	us-gaap	Standard Product Warranty Accrual Additions From Business Acquisition StandardProductWarrantyAccrualAdditionsFromBusinessAcquisition	5429	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60776	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82936	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	977872	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	42	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	686856	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial instruments that potentially expose the Company to significant concentrations of credit risk consist principally of cash. The Company places its cash with financial institutions with high credit ratings.</p>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2047220120	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1142061477	shares
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8264145	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	42	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	3283	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	6939	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	300000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	300000	usd
CY2023Q4	bdpt	Accrued Interest Current AccruedInterestCurrent	139277	usd
CY2022Q4	bdpt	Accrued Interest Current AccruedInterestCurrent	101966	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1019	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1015	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	443579	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	409920	usd
CY2023Q4	bdpt	Convertible Notes Payable Before Unamortized Debt Discount ConvertibleNotesPayableBeforeUnamortizedDebtDiscount	374250	usd
CY2022Q4	bdpt	Convertible Notes Payable Before Unamortized Debt Discount ConvertibleNotesPayableBeforeUnamortizedDebtDiscount	389440	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	52592	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	7647	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	321658	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	381793	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	321658	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	381793	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	43062	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	49402	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	137955	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	100919	usd
CY2023	bdpt	Amortization Of Debt Discount AmortizationOfDebtDiscount	119555	usd
CY2022	bdpt	Amortization Of Debt Discount AmortizationOfDebtDiscount	239186	usd
CY2023	us-gaap	Debt Instrument Convertible If Converted Value In Excess Of Principal DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal	109690	usd
CY2023	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	6026	usd
CY2023	bdpt	Convertible Shares Of Common Stock ConvertibleSharesOfCommonStock	443205460	shares
CY2023	bdpt	Proceeds From Issuances Of Common Stock ProceedsFromIssuancesOfCommonStock	166396	usd
CY2022	us-gaap	Debt Instrument Convertible If Converted Value In Excess Of Principal DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal	238510	usd
CY2022	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	11582	usd
CY2022	bdpt	Convertible Shares Of Common Stock ConvertibleSharesOfCommonStock	201734985	shares
CY2022	bdpt	Proceeds From Issuances Of Common Stock ProceedsFromIssuancesOfCommonStock	271587	usd
CY2023	bdpt	Value Assigned Of Derivatives Liabilities ValueAssignedOfDerivativesLiabilities	728213	usd
CY2023	bdpt	Debt Discount DebtDiscount	150000	usd
CY2023	bdpt	Derivative Loss On Derivative1 DerivativeLossOnDerivative1	578213	usd
CY2022	bdpt	Value Assigned Of Derivatives Liabilities ValueAssignedOfDerivativesLiabilities	276414	usd
CY2022	bdpt	Debt Discount DebtDiscount	217000	usd
CY2022	bdpt	Derivative Loss On Derivative1 DerivativeLossOnDerivative1	59414	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	557042	usd
CY2022	bdpt	Addition Of New Derivatives Recognized As Debt Discounts AdditionOfNewDerivativesRecognizedAsDebtDiscounts	217000	usd
CY2022	bdpt	Addition Of New Derivatives Recognized As Loss On Derivatives AdditionOfNewDerivativesRecognizedAsLossOnDerivatives	59414	usd
CY2022	bdpt	Settled On Issuance Of Common Stock SettledOnIssuanceOfCommonStock	-271587	usd
CY2022	bdpt	Gain Loss On Change In Fair Value Of The Derivative Liabilities GainLossOnChangeInFairValueOfTheDerivativeLiabilities	124987	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	686856	usd
CY2023	bdpt	Addition Of New Derivatives Recognized As Debt Discounts AdditionOfNewDerivativesRecognizedAsDebtDiscounts	150000	usd
CY2023	bdpt	Addition Of New Derivatives Recognized As Loss On Derivatives AdditionOfNewDerivativesRecognizedAsLossOnDerivatives	578213	usd
CY2023	bdpt	Settled On Issuance Of Common Stock SettledOnIssuanceOfCommonStock	-166396	usd
CY2023	bdpt	Gain Loss On Change In Fair Value Of The Derivative Liabilities GainLossOnChangeInFairValueOfTheDerivativeLiabilities	-270801	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	977872	usd
CY2023	bdpt	Loss On Derivative Instruments Related Convertible Notes LossOnDerivativeInstrumentsRelatedConvertibleNotes	578213	usd
CY2022	bdpt	Loss On Derivative Instruments Related Convertible Notes LossOnDerivativeInstrumentsRelatedConvertibleNotes	59414	usd
CY2023	bdpt	Gain Loss On Change In Fair Value Of The Derivative Liabilities GainLossOnChangeInFairValueOfTheDerivativeLiabilities	-270801	usd
CY2022	bdpt	Gain Loss On Change In Fair Value Of The Derivative Liabilities GainLossOnChangeInFairValueOfTheDerivativeLiabilities	124987	usd
CY2023	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	307412	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	184401	usd
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1250000000	shares
CY2023	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	443205460	shares
CY2023	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	282112	usd
CY2022	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	201734985	shares
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	521679	usd
CY2023	bdpt	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm	P2Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.35	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0131	pure
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	25272	usd
CY2023	us-gaap	Interest Paid InterestPaid	273	usd
CY2022	us-gaap	Interest Paid InterestPaid	533	usd
CY2023Q4	bdpt	Notes Payable To Related Parties Noncurrent NotesPayableToRelatedPartiesNoncurrent	5144	usd
CY2022Q4	bdpt	Notes Payable To Related Parties Noncurrent NotesPayableToRelatedPartiesNoncurrent	8444	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1320	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1047	usd
CY2023	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.04	pure
CY2023	bdpt	Term Of Notes Payable TermOfNotesPayable	P1Y
CY2022	bdpt	Increase Decrease In Accrued Salaries Payable IncreaseDecreaseInAccruedSalariesPayable	133334	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	300000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	25429	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5429	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9988	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2439	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15441	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2990	usd
CY2023	bdpt	Term Of Licenses Range Description TermOfLicensesRangeDescription	The term of licenses is a range from 1 to 3 years for certain products
CY2023	bdpt	Amortization Expense AmortizationExpense	28174	usd
CY2022	bdpt	Amortization Expense AmortizationExpense	62148	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	6166	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	6000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	0	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15166	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	59955	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	99116	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	59955	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	99116	usd
CY2023Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	0	usd
CY2022Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	0	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	585167	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	525212	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	585167	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	525212	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Gain Loss On Sale Of Leased Assets Net Operating Leases GainLossOnSaleOfLeasedAssetsNetOperatingLeases	2787000	usd
CY2023	us-gaap	Interest Expense Time Deposits InterestExpenseTimeDeposits	4510	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	2500	usd
CY2023Q4	bdpt	Marketing Of Common Shares Description MarketingOfCommonSharesDescription	On October 11 2023, the Company filed a new Reg A for the marketing of 250,000,000 common shares at a price range of $0.001 to $0.003, to be determined after qualifying

Files In Submission

Name	View Source	Status
0001640334-24-000602-index-headers.html	Edgar Link	pending
0001640334-24-000602-index.html	Edgar Link	pending
0001640334-24-000602.txt	Edgar Link	pending
0001640334-24-000602-xbrl.zip	Edgar Link	pending
bdpt-20231231.xsd	Edgar Link	pending
bdpt_10k.htm	Edgar Link	pending
bdpt_10kimg7.jpg	Edgar Link	pending
bdpt_ex311.htm	Edgar Link	pending
bdpt_ex312.htm	Edgar Link	pending
bdpt_ex321.htm	Edgar Link	pending
bdpt_ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
bdpt-20231231_cal.xml	Edgar Link	unprocessable
bdpt-20231231_def.xml	Edgar Link	unprocessable
bdpt-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bdpt-20231231_pre.xml	Edgar Link	unprocessable
bdpt_10k_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BDPT
BIOADAPTIVES, INC. Stock $bdpt

2024 Q1 Form 10-K Financial Statement

#000164033424000602 Filed on April 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDPT BIOADAPTIVES, INC. Stock $bdpt

2024 Q1 Form 10-K Financial Statement

#000164033424000602 Filed on April 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDPT
BIOADAPTIVES, INC. Stock $bdpt